BDX · CIK 0000010795
What BECTON DICKINSON & CO told the SEC could break it.
Most of what Becton Dickinson flagged is regulatory. The sharpest item is a live enforcement action: a November 2024 FDA Warning Letter over the quality system at its BD Pyxis dispensing facility in San Diego, for which it had accrued $98 million in estimated remediation costs as of September 30, 2025. Two more regulatory pressures sit alongside — the possible expansion of China's volume-based procurement, which imposes aggressive centralized price controls on medical devices, and intensifying scrutiny of ethylene-oxide sterilization that could hit BD and its third-party sterilizers. Reinforcing the operational risk, certain raw materials and components come from sole suppliers, and qualifying alternates can take 3-18 months, or 1-3 years where clinical trials are required.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA Warning Letter — BD Dispensing facility San Diego; $98M liability accrued as of September 30, 2025high
BD received an FDA Warning Letter in November 2024 following inspection of its BD Pyxis Dispensing quality management system in San Diego, citing violations of quality system regulations and MDR regulation; the company has accrued $98 million for estimated future remediation costs as of September 30, 2025.
“The Company's liability recorded for estimated future costs associated with certain actions required to respond to the Warning Letter and to address the non-conformities was $ 98 million as of September 30, 2025.”
SEC filing →As of 2025 - China volume-based procurement expansion — reimbursement/pricing pressure on medical device sales in Chinamedium
BD discloses that any expansion of China's volume-based procurement (VBP) process could adversely affect its operations; the VBP program applies aggressive centralized price controls to medical devices and drugs sold in China.
“any expansion of the volume-based procurement process in China or the Center for Medicaid Services' Competitive Bidding Program, reimbursement policy changes or the implementation of similar cost-containment efforts”
Sole-source dependency
- unnamed sole-sourced raw materials and components — qualification of alternates requires 3-18 months (or 1-3 years if clinical trials required)medium
BD discloses that certain raw materials and components are available only from sole suppliers, and qualifying alternate sources requires 3-18 months without clinical trials or 1-3 years with clinical trials; reliance on sole suppliers creates greater exposure to shortages and price swings.
“We purchase many different types of raw materials and components used in our products, some of which are not available from multiple sources. In addition, for quality assurance, cost-effectiveness and other reasons, certain raw materials and components are purchased from sole suppliers. Our reliance on sole suppliers can create greater exposure to shortages, magnify price swings and increase the difficulty of negotiating favorable terms.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“we do not have guaranteed supply agreements with Thermo Fisher, Becton, Dickinson and Company or Avantor, which exposes us to the risk that these suppliers may choose to discontinue doing business with us at any time.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch